Natco Pharma Limited — PPTs, 12-08-2025: Investor Presentation

Here's a summary of the Q1FY26 earnings presentation:

**1. Financial Highlights:**

Q1FY26 total revenue INR 1,390.6 Cr, profit after tax INR 480.3 Cr, with 45.5% EBITDA margin and EPS of INR 26.84. Net cash INR 3,474.0 Cr.

**2. Strategic Initiatives & Growth Drivers:**

NATCO expands its US pipeline with over 20 Para IV FTF opportunities, including Ozempic. Strategic investments: US$8 Mn in xenotransplantation, US$2 Mn in CAR-T/gene therapies (human dosing for Leukemia soon). A Phase 2 trial for its NCE (NRC-2694) in Head & Neck cancer is ongoing in the US and India.

**3. Market Position, Business Developments & Competitive Advantage:**

Export formulations drove 78.6% of Q1FY26 revenue, domestic 8.4%. The company's focus on complex generics (Para IV/FTF) for the US market provides a strategic edge. Investments in novel drug discovery and advanced therapies (cell & gene therapy) solidify its innovative market standing.

**4. Investor Implications:**

Robust financials, an aggressive pipeline, and cutting-edge biotech investments signal positive long-term growth potential. The dual focus on complex generics and innovation offers a competitive advantage; execution on NCE and cell therapy trials will be critical.